Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
Vabysmo (faricimab injection) now publicly funded for macular oedema secondary to retinal vein occlusion in Ontario
29 August 2025 - Roche Canada is pleased to announce today that Vabysmo (faricimab injection) is now publicly funded for ...
Posted by Michael Wonder on 22 Aug 2025
Leqvio advances toward broader access with agreement between Novartis and the pan-Canadian Pharmaceutical Alliance
21 August 2025 - Eligible Canadian patients with heterozygous familial hypercholesterolaemia are one step closer to publicly funded access to ...
Posted by Michael Wonder on 16 Aug 2025
Vabysmo (faricimab injection) now publicly funded for macular oedema secondary to retinal vein occlusion and pre-filled syringe in Quebec
15 August 2025 - Vabysmo now covered across all three approved indications in the province, providing patients with a comprehensively ...
Posted by Michael Wonder on 08 Aug 2025
Alexion, AstraZeneca Rare Disease reaches an agreement with the pan-Canadian Pharmaceutical Alliance for Ultomiris for the treatment of adults with neuromyelitis optica spectrum disorder and adults with generalised myasthenia gravis
7 August 2025 - The agreement is a critical step in ensuring adult patients living with NMOSD and gMG have ...
Posted by Michael Wonder on 08 Aug 2025
Access to multiple sclerosis treatments inadequate in British Columbia
7 August 2025 - Teresa Alfeld, a filmmaker who was recently diagnosed with multiple sclerosis, is calling for the provincial ...
Posted by Michael Wonder on 30 Jul 2025
CDA issues positive reimbursement recommendation for Skyclarys (omaveloxolone), the only Health Canada approved treatment for managing Friedreich ataxia
29 July 2025 - Biogen Canada is pleased to announce a significant step forward for Canadians living with Friedreich ataxia, ...
Posted by Michael Wonder on 30 Jul 2025
Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement on Cosentyx for hidradenitis suppurativa (
23 July 2025 - Following this important milestone, Cosentyx has been listed in Québec. ...
Posted by Michael Wonder on 06 Jun 2025
Biogen disappointed by INESSS recommendation on Skyclarys and its impact on Quebec patients with Friedreich ataxia
5 June 2025 - Biogen Canada is disappointed by INESSS's recommendation against listing Skyclarys (omaveloxolone), despite its therapeutic potential for ...
Posted by Michael Wonder on 19 May 2025
Trump wants to ‘equalize’ and lower drug prices. Could Canada be impacted?
17 May 2025 - US President Donald Trump has launched a new effort to lower prescription drug prices for Americans ...
Posted by Michael Wonder on 28 Apr 2025
New position statement aims to guide the use of AI methods in health technology assessment
25 April 2025 - Canada’s Drug Agency has published a new position statement on the use of artificial intelligence methods ...
Posted by Michael Wonder on 18 Apr 2025
Canada’s Drug Agency announces new 5 year strategic plan
17 April 2025 - Canada’s Drug Agency announces a new 5-year strategic plan, Insight to Impact 2025–2030. ...
Posted by Michael Wonder on 27 Mar 2025
ViiV Healthcare announces reimbursement for Apretude for HIV-1 pre-exposure prophylaxis under the Non-Insured Health Benefits (NIHB) Program
25 March 2025 - ViiV Healthcare is pleased to announce that Apretude (cabotegravir tablets and extended release injectable suspension) is ...
Posted by Michael Wonder on 25 Mar 2025
Government of Canada signs bilateral agreement with Quebec for Drugs for Rare Diseases
21 March 2025 - In Canada, one in 12 people live with a rare disease, and for most people affected, the ...
Posted by Michael Wonder on 03 Mar 2025
Canada’s Drug Agency publishes new guidance for rare disease registries in Canada
28 February 2025 - On Rare Disease Day — a global event dedicated to raising awareness for the millions of ...
Posted by Michael Wonder on 01 Mar 2025
Bimzelx (bimekizumab) negotiations with pCPA concluded successfully following positive CDA and INESSS recommendations for adults with active psoriatic arthritis and adults with active ankylosing spondylitis
28 February 2025 - Positive CDA and INESSS reimbursement recommendations are an important step towards public access to Bimzelx, the first ...